115 related articles for article (PubMed ID: 28933335)
1. Re-evaluating TTF-1 immunohistochemistry in diffuse gliomas: Expression is clone-dependent and associated with tumor location.
Pratt D; Afsar N; Allgauer M; Fetsch P; Palisoc M; Pittaluga S; Quezado M
Clin Neuropathol; 2017; 36(6):263-271. PubMed ID: 28933335
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and molecular implications of aberrant thyroid transcription factor-1 expression in colorectal carcinomas: an immunohistochemical analysis of 1319 cases using three different antibody clones.
Bae JM; Kim JH; Park JH; Park HE; Cho NY; Kang GH
Histopathology; 2018 Feb; 72(3):423-432. PubMed ID: 28914964
[TBL] [Abstract][Full Text] [Related]
3. TTF-1 may not be a reliable marker for differentiating metastasis from brain tumors.
Unal B; Yildirim S; Sezer C; Süren D
Turk Patoloji Derg; 2014; 30(3):201-5. PubMed ID: 24913303
[TBL] [Abstract][Full Text] [Related]
4. The Incidence of Labelling of Non-Lung Adenocarcinomas With Antibodies Against TTF-1 and Diagnostic Implications.
Prabhakaran S; Woo WLW; Xing G; Moffat D; Hussey M; Henderson DW; Klebe S
Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):471-476. PubMed ID: 31135446
[TBL] [Abstract][Full Text] [Related]
5. Thyroid transcription factor-1 in primary CNS tumors.
Kristensen MH; Nielsen S; Vyberg M
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):437-43. PubMed ID: 21325940
[TBL] [Abstract][Full Text] [Related]
6. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.
Rajeswarie RT; Rao S; Nandeesh BN; Yasha TC; Santosh V
J Clin Pathol; 2018 Apr; 71(4):323-329. PubMed ID: 28801347
[TBL] [Abstract][Full Text] [Related]
7. TTF-1 expression in breast carcinoma: an unusual but real phenomenon.
Ni YB; Tsang JY; Shao MM; Chan SK; Tong J; To KF; Tse GM
Histopathology; 2014 Mar; 64(4):504-11. PubMed ID: 24111789
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Utility of Thyroid Transcription Factor-1 in Ovarian Carcinoma and Its Relationship With Clinicopathologic Prognostic Parameters.
Hakim SA; Youssef NS
Appl Immunohistochem Mol Morphol; 2017 Apr; 25(4):237-243. PubMed ID: 26657873
[TBL] [Abstract][Full Text] [Related]
9. Significant expression of thyroid transcription factor-1 in pulmonary squamous cell carcinoma detected by SPT24 monoclonal antibody and CSA-II system.
Kashima K; Hashimoto H; Nishida H; Arakane M; Yada N; Daa T; Yokoyama S
Appl Immunohistochem Mol Morphol; 2014; 22(2):119-24. PubMed ID: 23531851
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases.
Vidarsdottir H; Tran L; Nodin B; Jirström K; Planck M; Mattsson JSM; Botling J; Micke P; Jönsson P; Brunnström H
Am J Clin Pathol; 2018 Oct; 150(6):533-544. PubMed ID: 30169783
[TBL] [Abstract][Full Text] [Related]
11. Aberrant TTF-1 Expression in Peripheral T-Cell Lymphomas: A Diagnostic Pitfall.
Chang ST; Chen SW; Chen BJ; Pan ST; Karube K; Chuang SS
Int J Surg Pathol; 2021 Apr; 29(2):165-168. PubMed ID: 32772757
[TBL] [Abstract][Full Text] [Related]
12. Positivity for GATA3 and TTF-1 (SPT24), and Negativity for Monoclonal PAX8 Expand the Biomarker Profile of the Solid Cell Nests of the Thyroid Gland.
Gucer H; Mete O
Endocr Pathol; 2018 Mar; 29(1):49-58. PubMed ID: 29313264
[TBL] [Abstract][Full Text] [Related]
13. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems.
Zhang PJ; Gao HG; Pasha TL; Litzky L; Livolsi VA
Int J Gynecol Pathol; 2009 Jan; 28(1):10-8. PubMed ID: 19047914
[TBL] [Abstract][Full Text] [Related]
14. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
15. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors.
Matoso A; Singh K; Jacob R; Greaves WO; Tavares R; Noble L; Resnick MB; Delellis RA; Wang LJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):142-9. PubMed ID: 19887917
[TBL] [Abstract][Full Text] [Related]
16. Thyroid transcription factor-1 expression in colorectal adenocarcinomas.
Dettmer M; Kim TE; Jung CK; Jung ES; Lee KY; Kang CS
Pathol Res Pract; 2011 Nov; 207(11):686-90. PubMed ID: 22019009
[TBL] [Abstract][Full Text] [Related]
17. Expression of CDX2 and Thyroid Transcription Factor-1 in Oropharyngeal Undifferentiated Carcinomas: A Potential Diagnostic Pitfall.
Chernock RD; Bibbey S; El-Mofty SK; Carpenter DH; Lewis JS
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):268-273. PubMed ID: 27389559
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
20. Expression of SOX11, PAX5, TTF-1 and ISL-1 in medulloblastoma.
Czapiewski P; Gorczynski A; Radecka K; Wiewiora C; Haybaeck J; Adam P; Fend F; Zakrzewska M; Zakrzewski K; Liberski PP; Biernat W
Pathol Res Pract; 2016 Nov; 212(11):965-971. PubMed ID: 27623204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
